Epigenetic regulation has become a promising therapeutic target due to its reversibility and crucial role in disease progression.Particularly,lysine-specific demethylase 1(LSD1)and histone deacetylases(HDAC)play vital roles in the gene regulation of cancer cells.This review discusses the research progress on single-target inhibitors for LSD1 and HDAC,as well as their dual-target inhibitors.Dual-target inhibitors,by simultaneously inhibiting the activity of both LSD1 and HDAC,provide stronger antitumor effects than single-target inhibitors and hold potential to improve treatment outcomes for patients.This review explores in detail the application of these three types of inhibitors in preclinical and clinical trials.
维普
万方数据